SQUILLACE, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 4.456
AS - Asia 2.554
EU - Europa 2.378
SA - Sud America 546
AF - Africa 56
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 10.000
Nazione #
US - Stati Uniti d'America 4.344
SG - Singapore 937
CN - Cina 543
IT - Italia 507
RU - Federazione Russa 438
BR - Brasile 426
HK - Hong Kong 424
DE - Germania 404
SE - Svezia 307
VN - Vietnam 300
IE - Irlanda 253
GB - Regno Unito 124
ID - Indonesia 115
CA - Canada 76
UA - Ucraina 70
IN - India 63
FI - Finlandia 48
AR - Argentina 47
DK - Danimarca 42
NL - Olanda 34
PL - Polonia 32
AT - Austria 29
KR - Corea 29
ZA - Sudafrica 28
MX - Messico 26
BD - Bangladesh 25
JP - Giappone 25
FR - Francia 23
EC - Ecuador 19
BE - Belgio 15
CO - Colombia 15
IQ - Iraq 14
TR - Turchia 13
PK - Pakistan 11
CH - Svizzera 10
PY - Paraguay 10
CL - Cile 9
ES - Italia 9
LT - Lituania 8
PE - Perù 8
KE - Kenya 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
MY - Malesia 6
AZ - Azerbaigian 5
CR - Costa Rica 5
EG - Egitto 5
CZ - Repubblica Ceca 4
IR - Iran 4
KZ - Kazakistan 4
PH - Filippine 4
SA - Arabia Saudita 4
SN - Senegal 4
TN - Tunisia 4
UY - Uruguay 4
UZ - Uzbekistan 4
BG - Bulgaria 3
BY - Bielorussia 3
EU - Europa 3
IL - Israele 3
MA - Marocco 3
MD - Moldavia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AU - Australia 2
KH - Cambogia 2
LU - Lussemburgo 2
MM - Myanmar 2
NG - Nigeria 2
NO - Norvegia 2
PR - Porto Rico 2
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
HR - Croazia 1
JO - Giordania 1
KG - Kirghizistan 1
MN - Mongolia 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
Totale 10.000
Città #
Ann Arbor 926
Singapore 577
Hong Kong 424
Ashburn 389
Frankfurt am Main 288
Fairfield 281
New York 260
Dublin 244
Chandler 240
Wilmington 198
Houston 143
Woodbridge 142
Santa Clara 107
Milan 105
Seattle 105
Jakarta 104
Los Angeles 99
Princeton 91
Beijing 88
Ho Chi Minh City 87
Cambridge 75
Dallas 73
Hefei 68
Dearborn 56
The Dalles 56
Hanoi 54
Jacksonville 52
São Paulo 43
Dong Ket 41
Lawrence 41
Shanghai 41
Chicago 39
Altamura 38
Moscow 37
London 32
Guangzhou 30
Buffalo 29
Seoul 29
Nanjing 28
Rome 28
Nuremberg 26
San Diego 26
Ottawa 24
Tokyo 24
Rio de Janeiro 22
Helsinki 21
Johannesburg 21
Warsaw 21
Brooklyn 18
Fremont 18
Vienna 16
Boston 15
Amsterdam 14
Andover 14
Brussels 14
Council Bluffs 14
Munich 14
Da Nang 13
Denver 13
Falls Church 13
Boardman 12
Montreal 12
Poplar 12
Lappeenranta 11
Monza 11
Phoenix 11
Stockholm 11
Toronto 11
Changsha 10
Chennai 10
Curitiba 10
Pune 10
Salt Lake City 10
Lachine 9
Nanchang 9
Palermo 9
Atlanta 8
Belo Horizonte 8
Biên Hòa 8
Edmonton 8
Elk Grove Village 8
Guayaquil 8
Hangzhou 8
Shenyang 8
Turin 8
Bogotá 7
Brasília 7
Carate Brianza 7
Columbus 7
Dhaka 7
Jinan 7
Manchester 7
Mexico City 7
Naples 7
Santo André 7
Zurich 7
Can Tho 6
Casorate Primo 6
Florence 6
Guarulhos 6
Totale 6.490
Nome #
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 307
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 281
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 277
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 276
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 273
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 263
Brachial and central blood pressure in HIV-infected subjects 261
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 258
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 257
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 245
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 235
Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare 233
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 225
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 219
Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment? 217
Weight gain: A possible side effect of all antiretrovirals 216
A multidisciplinary approach to screen the post-COVID-19 conditions 214
Unmasking tuberculosis in the era of antiretroviral treatment 214
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 213
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 206
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 201
Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti? 197
Arterial structure and function in AIDS patients: the impact of renal damage. 180
Ruolo delle strutture ambulatoriali extra-ospedaliere per pazienti con COVID-19: l’esperienza dell’Hotspot COVID di Monza. Role of outpatient facilities for patients with COVID-19: the experience of the COVID Hotspot in Monza. 176
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 171
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 163
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study 163
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 162
Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients. 156
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 156
Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible from the STOPSHIV Project Cohort 155
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study 148
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 147
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 146
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project 145
Factors Associated With Weight Gain in People Treated With Dolutegravir 142
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 141
Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort 141
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade 141
Factors associated with hospital admission for COVID-19 in HIV patients 140
Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study 139
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients 136
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 135
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 134
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 132
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing? 129
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens 128
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 126
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 126
Incident diabetes in course of antiretroviral therapy 125
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 125
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project 117
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study 114
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity? 113
Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda 109
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile 107
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir 107
HIV and SARS-CoV-2 Co-Infection: What are the Risks? 100
Reversibility of Central Nervous System Adverse Events in Course of Art 98
Totale 10.361
Categoria #
all - tutte 40.404
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.404


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021669 0 0 0 0 0 0 126 139 94 117 61 132
2021/2022692 75 63 82 61 19 48 18 34 18 60 68 146
2022/20231.272 135 346 108 104 67 193 23 103 84 21 50 38
2023/20241.037 51 18 69 29 119 315 165 48 83 27 7 106
2024/20252.021 92 219 107 116 175 135 109 57 193 341 174 303
2025/20262.842 576 451 373 581 571 257 33 0 0 0 0 0
Totale 10.361